MDT
Medtronic PLC
NYSE: MDT · HEALTHCARE · MEDICAL DEVICES
$79.34
+1.54% today
Updated 2026-06-18
Market cap
$103.20B
P/E ratio
21.55
P/S ratio
2.84x
EPS (TTM)
$3.73
Dividend yield
3.54%
52W range
$73 – $105
Volume
10.3M
WallStSmart proprietary scores
62
out of 100
Grade: C+
Hold
Investment rating
6.7
Growth
B4.8
Quality
C6.5
Profitability
B5.3
Valuation
C+2/9
Piotroski F-Score
Weak
—
Altman Z-Score
—
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$108.89
+37.24%
12-Month target
$77.52
-2.29%
Intrinsic (DCF)
$91.83
Margin of safety
+11.45%
2 Strong Buy15 Buy13 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Free cash flow $2.08B — positive
+ 11.45% below intrinsic value
Risks
- Piotroski 2/9 — weak financial health
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2023 | 2024 | 2025 | 2026 | TTM | 2027 (E) |
|---|---|---|---|---|---|---|
| Revenue | $31.23B | $32.36B | $33.54B | $36.36B | $36.36B | $39.0B |
| Net income | $3.76B | $3.68B | $4.66B | $4.80B | $1.24B | — |
| EPS | — | — | — | — | $3.73 | $6.14 |
| Free cash flow | $4.58B | $5.20B | $5.18B | $5.43B | $2.08B | — |
| Profit margin | 12.03% | 11.36% | 13.90% | 13.20% | 13.20% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-08 | KIIL, HARRY SKIP | Sale | 3,961 | $80.44 |
| 2026-06-08 | KIIL, HARRY SKIP | Sale | 228 | $80.45 |
| 2026-06-05 | BLOMQUIST, DENISE L. | Sale | 237 | $83.32 |
Peer comparison
Smart narrative
Medtronic PLC trades at $79.34. representing a P/E of 21.55x trailing earnings. Our Smart Value Score of 62/100 indicates the stock is good. The company scores 2/9 on the Piotroski F-Score. TTM revenue stands at $36.36B. with profit margins at 13.20%. Our DCF model estimates intrinsic value at $91.83.
Frequently asked questions
What is Medtronic PLC's stock price?
Medtronic PLC (MDT) trades at $79.34, on a P/E of 21.6x and a P/S of 2.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Medtronic PLC overvalued?
Medtronic PLC carries a Smart Value Score of 62/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $91.83 versus the $79.34 price, a 11.4% margin of safety on a cash flow basis.
What is the price target of Medtronic PLC (MDT)?
The 12-month analyst consensus target is $108.89, about 37.2% above the current $79.34. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of MDT by 2030?
Our research-backed model puts the 2030 base case at $441.81, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Medtronic PLC (MDT)?
Our DCF model estimates intrinsic value at $91.83, a +11.4% margin of safety versus today's $79.34. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.
What is Medtronic PLC's revenue?
Medtronic PLC's trailing twelve-month revenue is $36.36B, and our model projects it reaching about $46.89B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Company info
SectorHEALTHCARE
IndustryMEDICAL DEVICES
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio2.84x
ROE9.80%
Beta0.60
50D MA$80.59
200D MA$92.11
Shares out1.28B
Float1.28B
Short ratio—
Avg volume10.3M
Performance
1 week+0.00%
1 month+4.50%
3 months-4.44%
YTD-14.98%
1 year—
3 years—
5 years—